Cryoport, Inc. (CYRX) Company Overview

What does Cryoport do?

Cryoport, Inc. is a Nasdaq-listed life-sciences infrastructure company that moves, stores, manages, and protects high-value biological materials under controlled temperatures. It operates between therapy developers and patients, where custody, identity, condition, and timing must be documented. Cryoport combines logistics, biostorage, bioservices, cryogenic equipment, reusable shipping systems, and informatics rather than functioning as a conventional parcel carrier.

A specialized life-sciences infrastructure company

The company’s investor overview describes a global integrated platform built for temperature-controlled supply chains. The practical distinction is important. A missed delivery for an ordinary product creates inconvenience; a deviation involving patient-specific cell therapy can invalidate a dose, delay treatment, trigger investigation, or compromise a clinical trial. That risk makes validation, chain-of-custody records, trained personnel, qualified packaging, and contingency procedures part of the product.

Customers, end markets, and geographic reach

Customers include biopharmaceutical companies, research organizations, manufacturers, hospitals, laboratories, distributors, animal-health businesses, and reproductive-medicine providers. Cell and gene therapy is the strategic center because its supply chains are patient-linked, temperature-sensitive, and highly regulated. MVE equipment also serves broader biologics and animal-health uses.

How does Cryoport make money?

Cryoport has two complementary revenue engines. Life Sciences Services includes BioLogistics and BioStorage/BioServices; Life Sciences Products primarily includes MVE cryogenic storage, transportation, and handling equipment. Products supply physical infrastructure, while services manage recurring workflows around biological materials.

Services create embedded, repeat-use demand

BioLogistics generated $78.1 million in FY2025, while BioStorage/BioServices generated $18.4 million. A customer may begin with a clinical-trial lane, then add storage, packaging, labeling, sample management, or launch support. Revenue is not subscription-based, but validated lanes, recurring shipments, stored inventory, and long programs can make demand repeatable.

Products provide vertical integration and installed-base exposure

The products business sells equipment to laboratories, manufacturers, distributors, and healthcare institutions. Demand can be more capital-cycle-sensitive than services, but MVE provides manufacturing capability, an installed base, and cross-selling opportunities.

The 2025 Form 10-K is the most useful source for the segment definitions, revenue disaggregation, customer concentration, and competitive context.

What does Cryoport’s first quarter of 2026 show?

The quarter ended March 31, 2026 showed broad growth and better adjusted performance, but not sustained GAAP profitability. Revenue increased 16% to $47.8 million. Services rose 18% to $26.9 million and Products rose 15% to $20.9 million. Commercial cell-and-gene-therapy revenue increased 26% to $9.1 million, while clinical-trial support revenue increased 18% to $12.9 million.

Growth is broad, but operating spending still exceeds gross profit

Cash flow improved, while capital expenditure accelerated

The latest Q1 2026 earnings release provides management’s summary, while the March 2026 Form 10-Q contains the complete statements and disaggregated revenue. The key analytical tension is clear: revenue and gross profit are advancing, but the company must convert that growth into operating leverage while funding capacity.

Which turning points shaped Cryoport’s current model?

Cryoport evolved by expanding scope: validating specialized shipping systems, adding biostorage and bioservices, acquiring cryogenic-equipment manufacturing, and later pruning the portfolio around higher-value life-sciences infrastructure. The official company history shows how those decisions created the current platform.

From a single service to a coordinated platform

The acquisitions changed both revenue mix and strategic control. Biostorage increased the duration of customer relationships. MVE added manufacturing and equipment expertise. Cell-processing capabilities moved the company closer to the therapy’s starting material. Together, these assets support a value-chain argument: Cryoport can solve multiple failure points under one operating framework, while data generated across those activities improves visibility and auditability.

The 2025 portfolio reset sharpened the investment question

Divesting CRYOPDP simplified the story but also requires careful historical comparison because discontinued operations created a large one-time accounting gain in FY2025. The ongoing company is more focused on life-sciences services, products, and specialized partnerships. Researchers therefore should evaluate continuing operations rather than extrapolating consolidated net income that included the divested business.

Chain of Compliance and global infrastructure define the moat

Cryoport’s competitive advantage is not one patent or one shipping container. It is a system of qualified equipment, operating procedures, software, facilities, trained personnel, regulatory knowledge, and historical performance. The company calls this approach its Chain of Compliance: documenting custody, condition, and identity through the shipment and storage lifecycle. For patient-specific therapies, those records are integral to quality assurance rather than administrative extras.

Why validation and compliance can create switching costs

A therapy sponsor qualifies packaging, routes, monitoring devices, handling procedures, and contingencies before use. Switching may require revalidation, new procedures, documentation, retraining, and risk to trial continuity. Cryoport also benefits from long cell-and-gene-therapy experience, global coverage, and relationships that can expand from clinical development into commercialization.

Why the moat is not absolute

Large logistics groups can invest in healthcare capabilities, customers can maintain internal solutions, and specialized competitors can excel in individual niches. Cryoport must continuously demonstrate reliability, regulatory compliance, technology relevance, and competitive pricing. The moat therefore depends on execution: a quality failure, cyber incident, capacity shortfall, or poor integration outcome could damage precisely the trust that makes the model defensible.

Who competes with Cryoport, and where is it differentiated?

Competition varies by activity. Cryoport identifies World Courier, UPS Healthcare, Quick, and Biocair in specialty logistics, plus Azenta Life Sciences, Phase 2, and IC Biomedical in cryogenic equipment. Customers can also build internal capabilities. Cryoport therefore competes across adjacent markets rather than controlling one category.

Cryoport occupies a high-specialization, moderate-scale position

Cryoport is most differentiated when customers value an integrated, validated workflow over the lowest unit price. It is less differentiated in standardized equipment or simple shipping lanes. Market position should therefore be judged through service mix, commercial therapy adoption, retention, and margin.

How financially strong is Cryoport?

Cryoport entered 2026 with substantial liquidity but not mature earnings power. At March 31, cash and equivalents were $272.9 million and short-term investments were $130.7 million, or $403.6 million combined. Working capital was $245.7 million, while $186.2 million principal of convertible notes was due in December 2026. That maturity makes cash preservation and capital deployment important.

Liquidity versus the December 2026 maturity

Core profitability versus divestiture accounting

FY2025 revenue was $176.2 million and gross profit was $83.1 million, a 47.1% margin. SG&A of $102.8 million and engineering and development expense of $17.0 million contributed to a $36.8 million operating loss. Reported net income of $78.3 million included $112.3 million from discontinued operations, while continuing operations lost $34.0 million. A DCF should normalize the divestiture effect.

Who owns Cryoport stock, and why does governance matter?

Cryoport has a one-vote-per-common-share structure, but its investor profile is not purely dispersed. The 2026 proxy statement reported 50.2 million common shares outstanding for the ownership table and 200,000 Series C convertible preferred shares. Blackstone affiliates owned all Series C preferred shares and, on an as-converted basis, represented the largest disclosed beneficial position.

Voting influence and incentive alignment

The six-member board combined Shelton’s chair and chief executive roles with an independent lead director and independent committees. Investors should track equity compensation, preferred-share conversion economics, board oversight, and whether capital allocation prioritizes the note maturity, organic investment, acquisitions, or repurchases.

What opportunities and risks could change Cryoport’s story?

Cryoport’s opportunity is tied to the industrialization of advanced therapies. Progression from clinical work to commercial launch can require more shipments, storage, coordination, lanes, and stricter service levels. The 91 supported Phase 3 trials at March 31, 2026 form a potential approval pool, but programs can fail, pause, or launch slowly.

Growth catalysts

Company-specific constraints

In Q1 2026, the Americas produced $35.0 million of revenue, EMEA $9.0 million, and APAC $3.9 million. International expansion can diversify demand but adds currency, customs, regulatory, and execution complexity.

What should a DCF model and research brief monitor next?

Cryoport’s revenue growth, strategic exposure, liquidity, and accounting profit point in different directions. A disciplined model should begin with continuing operations, separate divestiture effects, and forecast Services and Products independently. Gross margin should reflect mix, while overhead and development spending determine whether gross-profit growth reaches operating income.

Valuation mechanics that matter most

The key assumptions are conversion of late-stage programs, revenue per commercial therapy, retention, gross-margin improvement, overhead discipline, and normalized capex. Terminal value is sensitive because continuing operations remain loss-making. Assuming mature margins too quickly can overstate value; ignoring embedded workflows and the commercial pipeline can understate leverage.

Comparable-company analysis also requires care because Cryoport mixes specialty logistics, biostorage, bioservices, and cryogenic products. Revenue multiples should be cross-checked against growth quality, gross margin, cash burn, net liquidity after the note maturity, and commercial-therapy exposure. The mission matters only if reliability converts into retention, scale, and cash flow.